Details for: ZELDOX
Company: UPJOHN CANADA ULC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02298597 | ZELDOX | ZIPRASIDONE (ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE) | 20 MG | CAPSULE | ORAL |
| 02298600 | ZELDOX | ZIPRASIDONE (ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE) | 40 MG | CAPSULE | ORAL |
| 02298619 | ZELDOX | ZIPRASIDONE (ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE) | 60 MG | CAPSULE | ORAL |
| 02298627 | ZELDOX | ZIPRASIDONE (ZIPRASIDONE HYDROCHLORIDE MONOHYDRATE) | 80 MG | CAPSULE | ORAL |
Summary Reports
Summary Basis of Decision
Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Sleep Apnoea
Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Urinary Retention
Summary Safety Review - Atypical Antipsychotics - Liver failure
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of sleep walking and sleep-related eating disorder
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Sleep Apnoea
Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Urinary Retention
Summary Safety Review - Atypical Antipsychotics - Liver failure
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of sleep walking and sleep-related eating disorder
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.